Trial · NCT04124965
Adverse events38
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 38
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Rozanolixizumab ~7 mg/kg | 6 | 50 | 11 |
| other | Diarrhoea | Gastrointestinal disorders | Rozanolixizumab ~10 mg/kg | 7 | 42 | 10 |
| other | Abdominal pain | Gastrointestinal disorders | Rozanolixizumab ~7 mg/kg | 2 | 50 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Rozanolixizumab ~10 mg/kg | 2 | 42 | 2 |
| other | Nausea | Gastrointestinal disorders | Rozanolixizumab ~7 mg/kg | 4 | 50 | 4 |
| other | Nausea | Gastrointestinal disorders | Rozanolixizumab ~10 mg/kg | 5 | 42 | 8 |
| other | Vomiting | Gastrointestinal disorders | Rozanolixizumab ~7 mg/kg | 0 | 50 | 0 |
| other | Vomiting | Gastrointestinal disorders | Rozanolixizumab ~10 mg/kg | 4 | 42 | 4 |
| other | Pyrexia | General disorders | Rozanolixizumab ~7 mg/kg | 4 | 50 | 5 |
| other | Pyrexia | General disorders | Rozanolixizumab ~10 mg/kg | 3 | 42 | 4 |
| other | Hypogammaglobulinaemia | Immune system disorders | Rozanolixizumab ~7 mg/kg | 2 | 50 | 4 |
| other | Hypogammaglobulinaemia | Immune system disorders | Rozanolixizumab ~10 mg/kg | 2 | 42 | 2 |
| other | Nasopharyngitis | Infections and infestations | Rozanolixizumab ~7 mg/kg | 2 | 50 | 2 |
| other | Nasopharyngitis | Infections and infestations | Rozanolixizumab ~10 mg/kg | 4 | 42 | 4 |
| other | Urinary tract infection | Infections and infestations | Rozanolixizumab ~7 mg/kg | 5 | 50 | 5 |
| other | Urinary tract infection | Infections and infestations | Rozanolixizumab ~10 mg/kg | 2 | 42 | 2 |
| other | Blood immunoglobulin G decreased | Investigations | Rozanolixizumab ~7 mg/kg | 6 | 50 | 12 |
| other | Blood immunoglobulin G decreased | Investigations | Rozanolixizumab ~10 mg/kg | 5 | 42 | 6 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Rozanolixizumab ~7 mg/kg | 2 | 50 | 2 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Rozanolixizumab ~10 mg/kg | 3 | 42 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04124965/events